Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
114 EUR | +0.13% | -.--% | -.--% |
Jun. 03 | Global markets live: GSK, Walt Disney, Blackstone, Boeing, Microsoft... | |
Jun. 03 | Dsm-firmenich to De-prioritize Certain Business Activities Under New Strategy | MT |
Sales 2024 * | 12.62B 13.73B | Sales 2025 * | 13.27B 14.44B | Capitalization | 27.19B 29.59B |
---|---|---|---|---|---|
Net income 2024 * | 453M 493M | Net income 2025 * | 813M 885M | EV / Sales 2024 * | 2.39 x |
Net Debt 2024 * | 2.92B 3.17B | Net Debt 2025 * | 2.66B 2.9B | EV / Sales 2025 * | 2.25 x |
P/E ratio 2024 * |
58.9
x | P/E ratio 2025 * |
33.6
x | Employees | 28,685 |
Yield 2024 * |
2.45% | Yield 2025 * |
2.41% | Free-Float | 25.03% |
Latest transcript on Koninklijke DSM
1 day | +0.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 57 | 89-12-31 | |
Ralf Schmeitz
DFI | Director of Finance/CFO | - | 23-08-31 |
Sarah Reisinger
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 23-01-31 | |
Thomas Leysen
CHM | Chairman | 63 | 23-01-31 |
Director/Board Member | 62 | 23-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.43% | 304 M€ | +16.98% | ||
1.13% | 17 M€ | +8.03% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.89% | 884B | |
+3.75% | 244B | |
+27.36% | 177B | |
-0.21% | 135B | |
+60.62% | 99.02B | |
-7.84% | 71.82B | |
-9.39% | 54.57B | |
+70.00% | 31.07B | |
-40.96% | 30.77B |
- Stock Market
- Equities
- DSFIR Stock
- DSM Stock